HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ahlke Heydemann Selected Research

Therapeutics

11/2023Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 - Month Follow-Up Study After Systemic Intraosseous Administration.
12/2022Intraosseous transplant of dystrophin expressing chimeric (DEC) cells improves skeletal muscle function in mdx mouse model of Duchenne muscular dystrophy.
10/2021Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle's function in Duchenne muscular dystrophy.
6/2018Skeletal Muscle Metabolism in Duchenne and Becker Muscular Dystrophy-Implications for Therapies.
6/2018Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy.
1/2018"Of Mice and Measures": A Project to Improve How We Advance Duchenne Muscular Dystrophy Therapies to the Clinic.
1/2017Severe murine limb-girdle muscular dystrophy type 2C pathology is diminished by FTY720 treatment.
2/2007Genetic modifiers of muscular dystrophy: implications for therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ahlke Heydemann Research Topics

Disease

16Muscular Dystrophies (Muscular Dystrophy)
11/2023 - 02/2004
15Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker)
03/2024 - 03/2009
8Fibrosis (Cirrhosis)
10/2021 - 10/2005
7Cardiomyopathies (Cardiomyopathy)
12/2012 - 03/2003
4Disease Progression
10/2021 - 01/2015
3Limb-Girdle Muscular Dystrophies (Limb-Girdle Muscular Dystrophy)
12/2012 - 10/2005
2Fatigue
12/2022 - 06/2018
2Respiratory Insufficiency (Respiratory Failure)
12/2022 - 10/2021
2Inflammation (Inflammations)
01/2017 - 01/2010
2Hypersensitivity (Allergy)
12/2014 - 02/2004
1Muscle Weakness
10/2021
1Cicatrix (Scar)
01/2021
1Mitochondrial Diseases (Mitochondrial Disease)
06/2018
1type 2C Limb-girdle muscular dystrophy
01/2017
1Wasting Syndrome (Wasting Disease)
01/2017
1Dysferlinopathy
03/2016
1Hypertrophy
09/2015
1Hyperinsulinism (Hyperinsulinemia)
12/2014
1Hyperglycemia
12/2014
1Aortic Aneurysm (Aneurysm, Aortic)
01/2010
1Thoracic Aortic Aneurysm
01/2010
1Atherosclerosis
01/2010
1Vascular Remodeling
01/2010
1Ischemia
03/2009
1Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
02/2007
1Muscular Diseases (Myopathy)
02/2007
1Spasm (Spasms)
03/2004
1Necrosis
03/2004
1Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy)
03/2003

Drug/Important Bio-Agent (IBA)

18DystrophinIBA
03/2024 - 02/2004
12Sarcoglycans (beta Sarcoglycan)IBA
01/2017 - 02/2004
7Proteins (Proteins, Gene)FDA Link
09/2015 - 03/2003
3Coloring Agents (Dyes)IBA
01/2015 - 10/2005
3Hydroxyproline (4 Hydroxyproline)IBA
01/2015 - 10/2005
3Evans Blue (Blue, Evans)FDA Link
01/2015 - 10/2005
2Biomarkers (Surrogate Marker)IBA
11/2023 - 03/2016
2Transforming Growth Factors (Transforming Growth Factor)IBA
09/2021 - 03/2011
2Nitric Oxide Synthase (NO Synthase)IBA
03/2004 - 02/2004
1Complementary DNA (cDNA)IBA
03/2023
1DecorinIBA
09/2021
1Peptides (Polypeptides)IBA
09/2021
1Adenosine Triphosphate (ATP)IBA
06/2018
1AMP-Activated Protein KinasesIBA
06/2018
1UtrophinIBA
06/2018
1Fingolimod Hydrochloride (FTY720)FDA Link
01/2017
1DysferlinIBA
03/2016
1Thrombospondin 1IBA
03/2016
1ThrombospondinsIBA
03/2016
1Glucose (Dextrose)FDA LinkGeneric
12/2014
1Annexin A6IBA
04/2014
1Membrane Proteins (Integral Membrane Proteins)IBA
03/2011
1LigandsIBA
01/2010
1S100A12 ProteinIBA
01/2010
1CollagenIBA
01/2010
1Matrix Metalloproteinase 2 (Gelatinase A)IBA
01/2010
1Transforming Growth Factor beta (TGF-beta)IBA
12/2009
1Proline (L-Proline)FDA Link
12/2009
1Latent TGF-beta Binding Proteins (Latent TGF beta Binding Protein)IBA
12/2009
1Amino AcidsFDA Link
12/2009
1Type 5 Cyclic Nucleotide PhosphodiesterasesIBA
03/2009
1SpectrinIBA
03/2009
1Ventricular MyosinsIBA
02/2007
1emerinIBA
02/2007
1Lamin Type A (Lamin A)IBA
02/2007
1CytokinesIBA
03/2004
1Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA
02/2004
1Glycoproteins (Glycoprotein)IBA
02/2004
1Adrenergic Agents (Adrenergic Drugs)IBA
02/2004
1Carbachol (Carbastat)FDA Link
02/2004

Therapy/Procedure

8Therapeutics
11/2023 - 02/2007
6Cell- and Tissue-Based Therapy (Cell Therapy)
11/2023 - 10/2021
1Transplantation
01/2021